Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (September 2026)
23 slides from Noxopharm's investor presentation, September 2026
Slide 1: Developing precision therapies for chronic inflammation, autoimmune diseases and cancer
Developing precision therapies for chronic inflammation, autoimmune diseases and cancer Noxopharm (ASX:NOX) Investor Presentation September 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (Noxopharm, NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in N
Slide 3: Noxopharm – Harnessing the immune system to fight disease
Noxopharm – Harnessing the immune system to fight disease Australian clinical-stage biotechnology company developing novel targeted immuno-therapies for chronic inflammation, autoimmune diseases and cancer Proprietary Sofra platform • Built upon a newly discovered role of natural RNA (Ribonucleic Ac
Slide 4: Our platform: The Sofra Tech Platform
Our platform Developing proprietary synthetic RNA-based medicines (oligonucleotides) >50% of all deaths are linked Market opportunity for precise, targeted to inflammation 1 therapies in place of broad immune suppression OUR SOLUTION The Sofra Tech Platform Turning natural RNA immune control into ta
Slide 5: How does Sofra technology work?
How does Sofra technology work? Translating naturally occurring immune-control into targeted medicines 1 2 3 4 Sofra decodes it from Sofra encoded RNA Application potential Nature’s off-switch discovery natural RNA medicines across therapeutic areas Natural RNA fragments help keep innate Noxopharm h
Slide 6: A strong and diverse pipeline
A strong and diverse pipeline A single technology platform supporting multiple immuno-therapy approaches Program Focus MoA Partner Discovery PoC IND-enabling Clinical SOF-SKN Topical therapy; initial focus on cutaneous lupus erythematosus TLR7/8 Internal Phase I complete; Phase II preparation Lead a
Slide 7: Near-term milestones and catalysts
Near-term milestones and catalysts Multiple potential value drivers over the next 12 months Next 12 months Systemic SOF-VAC SOF-CAN SOF-SKN autoimmune First patients First efficacy Confirmation of SOF-SKN PoC in vivo data from New collaborations Oncology in vivo recruited into signals from safety an
Slide 8: Lead asset and clinical progress
Lead asset and clinical progress AUTOIMMUNE DISEASES / INFLAMMATION 8
Slide 9: SOF-SKN innovation at a glance
SOF-SKN innovation at a glance Lead clinical asset for cutaneous lupus erythematosus (CLE) An autoimmune Cutaneous lupus Unmet need for well SOF-SKN is a What is disease that can affect erythematosus (CLE) tolerated targeted topical clinical Lupus? different organs. manifests in the skin. therapies.
Slide 10: Targeting global dermatology markets
Targeting global dermatology markets Initial focus on CLE valued at US$5.4 billion (2024) with no current targeted therapies Potential expansion into adjacent inflammatory skin diseases Selected inflammatory skin disease TAM ~US$43B (2025E) → ~US$56B (2034F) INITIAL CLINICAL ENTRY POINT EXPANSION OP
Slide 11: SOF-SKN: mechanism of action
SOF-SKN: mechanism of action Targeting overactive TLR7/8 signalling at the source of skin inflammation SOF-SKN promotes healing Overactive immune Targeted approach to Its active ingredient, receptors Toll-like SOF-SKN is applied reduce inflammatory TLR7/8 is a SOF-16, is designed receptors 7 and 8 (
Slide 12: The SOF-SKN competitive advantage
The SOF-SKN competitive advantage How SOF-SKN compares on clinical stage, mechanism, safety and durability Approved CLE Emerging oral Therapies TLR7/8 inhibitors SOF-SKN Enpatoran (Merck) / Topical TLR7/8 Kenalog / Plaquenil Inhibitor Afimetoran (BMS) Clinical stage In market Phase II / Phase III Ph
Slide 13: Progressive clinical trial strategy
Progressive clinical trial strategy Accelerating SOF-SKN’s clinical development in patients with CLE Q2 2027 Q4 2027 Q1 2027 Extension First patient treatment Initial efficacy signals in Full clinical data readout – patients Study (15 patients, 14 days’ daily Complete patient efficacy signals + safe
Slide 14: Platform opportunities
Platform opportunities mRNA VACCINE ADJUVANCY IMMUNO- ONCOLOGY 14
Slide 15: Tuning the immune system for mRNA vaccines and immuno-oncology
Tuning the immune system for mRNA vaccines and immuno-oncology SOF-VAC and SOF-CAN use the same underlying oligonucleotide technology Sofra Platform Encoding immune control into synthetic RNA oligonucleotides allows precision tuning of the immune system in two directions Targeted immune inhibition T
Slide 16: SOF-VAC - Enhancing mRNA medicines and vaccines
SOF-VAC - Enhancing mRNA medicines and vaccines Designed to limit side effects of mRNA vaccines SOF-VAC - mechanism of action Key advantages Reduces off-target reactogenic side effects of mRNA vaccines Enables potential for higher mRNA doses, increasing efficacy while maintaining safety Sofra RNA te
Slide 17: SOF-CAN - Precision immune activation to fight cancer
SOF-CAN - Precision immune activation to fight cancer Precision immune activation for next-generation cancer immunotherapy Current progress How SOF-CAN works and key advantages Ex vivo proof-of-concept announced, R&D at late-stage lead optimisation Toll-like receptor 8 (TLR8) in immune cells In vivo
Slide 18: Multiple opportunities in mRNA vaccines and immuno-oncology
Multiple opportunities in mRNA vaccines and immuno-oncology SOF-VAC and SOF-CAN use the same underlying oligonucleotide technology Technologies supporting higher, safer doses of mRNA Technologies selectively activating the immune system mRNA VACCINE ADJUVANCY IMMUNO-ONCOLOGY SOF-VAC USE CASES SOF-CA
Slide 19: Comprehensive IP strategy
Comprehensive IP strategy A growing patent portfolio supporting the Sofra platform and lead programs Long-term collaboration with Hudson Institute of Key HIMR collaboration discoveries were exclusively licensed to Noxopharm in Medical Research (HIMR) enabling ongoing research 2021. Four core patent
Slide 20: Experienced Management Team
Experienced Management Team Dr Olivier Laczka Shawn van Boheemen Dr Daniel Wenholz CEO CFO Director of Pharmaceutical Chemistry BSc, MSc, PhD BBus MCom, FCPA, JP BSc, PhD Experienced biotechnology and drug development 30 years’ commercial finance leadership experience across Experience across academ
Slide 21: Investment highlights
Investment highlights Clinical progress, platform potential and multiple value-driving catalysts • Clinical-stage lead asset: SOF-SKN has completed Phase I in healthy volunteers, with an extension study to include CLE patients in final preparation and Phase II planning underway. • Unique platform wi
Slide 22: Corporate overview
Corporate overview Key corporate and market information ASX code: NOX Pharmaceuticals, GICS classification: Biotechnology & Life Sciences Latest share price: $0.089 (as at 01/09/26) Market capitalisation $27.03M Shares on issue1: 307,237,950 52-week high: $0.135 12-month share price performance 52-w
Slide 23: Noxopharm (ASX:NOX)
Noxopharm (ASX:NOX) For more information, please contact: Dr Olivier Laczka Gaby Hold Chief Executive Officer The Capital Network E: Olivier.laczka@noxopharm.com E: gaby@thecapitalnetwork.com.au P: +61 2 9144 2223 P: +61 2 7257 7338 Website: www.noxopharm.com